Hence both pharmacological and genetic means of reducing 5-HT5A activity resulted in the same phenotypic consequences in breast tumor cell lines, suggesting that 5-HT5A is indeed required for BITC survival. The gene discussed is HTR5A; the disease is breast neoplasm.